welcome esmo immuno-oncology 2024 esmo's journal portfolio resources resources elsevier’s oncology journal network 続きを読む elsevier’s oncology journal network highlights 続きを読む
+ESMO is the leading European professional organisation for medical oncology. Comprising over 20,000 oncology professionals from over 150 countries, we are the society of reference for oncology education and information. We are committed to supporting our members to develop and advance in a fast-evol...
Conference|ESMO Congress Photos from the 2012 European Society for Medical Oncology (ESMO) congress, held at the Austria Center Vienna from September 28 to October 2, in Vienna, Austria.Photos from the 2012 European Society for Medical Oncology (ESMO) congress, held at the Austria Center Vienna ...
The European Society for Medical Oncology (ESMO) Author links open overlay panelShow more Add to Mendeley Share Cite https://doi.org/10.1093/annonc/mdu468Get rights and content Under an Elsevier user license open archivePrevious article in issue Next article in issue...
The European Society for Medical Oncology (ESMO) is a non-profit professional medical oncology society in Europe. ESMO offers post-graduate education and training in clinical cancer care and research, and produces evidence-based recommendations for basic standards of cancer care. ...
ESMO 2025 Congress - European Society for Medical Oncology, 2025, organized by ESMO - European Society for Medical Oncology. Find conference details | Conference Locate (Clocate)
European Society for Medical Oncology Home ECP 2019 Conference ESMO 2019 Congress Better answers today. Better care tomorrow. We are in the midst of a healthcare transformation away from the one-size-fits-all approach towards a more targeted, personalised approach that utilises pa...
High TILs may predict who may have a reduced risk for disease relapse or death in patients with early HER2-positive breast cancer treated with trastuzumab. Amivantamab/Chemo Shows Sustained OS in Advanced EGFR+ NSCLC Darlene Dobkowski, MA September 15th 2024 Amivantamab plus chemotherapy also imp...
ESMO 2025 Congress - European Society for Medical Oncology, 17-21 Oct 2025, Berlin, Germany, organized by ESMO - European Society for Medical Oncology. Find conference details | Conference Locate (Clocate)
Sep. 27, 2024 RBD-8088, a BBB-penetrating oligonucleotide with efficacy in glioblastoma models Suzhou Ribo Life Science Co. Ltd. recently reported on the development and preclinical characterization of a novel blood-brain barrier (BBB)-penetrating oligonucleotide drug, RBD-8088, for the treatment of...